Updated:
Flerie
Flerie is an active long-term life science investor that builds companies with pioneering pharmaceutical and biotech projects or adjacent capabilities.
Flerie
Flerie is an active long-term life science investor that builds companies with pioneering pharmaceutical and biotech projects or adjacent capabilities. The firm uses its network, expertise and resources to achieve long-term success for its portfolio companies. Flerie focuses on making a positive impact on health and well-being.
General information
Firm type
Generalist
Year founded
2011
Location
Region
Europe
Country
Sweden
City
Stockholm
Corporate office
Birger Jarlsgatan 13, 111 45 Stockholm, Sweden
Additional offices
London, United Kingdom · Matfors, Sweden
Principals
Thomas Eldered
Founder and Executive Chairman
Ted Fjällman
CEO of Flerie AB and Partner at Flerie Invest
Sector focus
Frequently asked questions
Who runs investment decisions at Flerie?
Investment operations are led by CEO and Partner Ted Fjällman, who reports to Founder and Executive Chairman Thomas Eldered. Eldered co-founded Recipharm, the CDMO sold to EQT in 2021, and his pharmaceutical operating experience shapes the firm's investment posture. Flerie emphasizes active, long-term stewardship rather than passive capital allocation.
Does Flerie maintain any operating assets beyond its investment portfolio?
Yes. Flerie holds NorthX Biologics, a biomanufacturing facility located in Matfors, Sweden. This industrial asset complements the firm's financial portfolio and provides direct operational exposure to biologics production — a differentiator from most life-science investment firms that hold only financial stakes.
How does Flerie source and support its portfolio companies?
The firm leverages its leadership's pharmaceutical operating background and an extensive network of Key Opinion Leaders, including clinicians featured in its Flerie Insights podcast series. Industry association memberships — the European Healthcare Investor Association, British Venture Capital Association, and SwedenBIO — provide additional sourcing channels. Flerie differentiates itself by actively advancing portfolio companies' clinical pipelines through hands-on involvement rather than purely financial engineering.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: